BioCryst, opgeblazen verwachting en euforie is nu al gezakt naar 50% to 85%
Daar scoor je ook geen olympische medaille meer mee.........
This is Bert on for Brian. Can you give us any further clarity on when we might see the APeX-2 data in second quarter? And then also, you've previously cited 50% as the bar for attack reduction. How does your market research, prior data, PK-PD mapping and OLE observations all shape your expectations for the readout and/or the threshold to try and meet? Thank you.
--------------------------------------------------------------------------------
Jon P. Stonehouse, BioCryst Pharmaceuticals, Inc. - CEO, President & Director [3]
--------------------------------------------------------------------------------
Sure, Bert. I'll take that. So no, we're not giving any further granularity on timing other than to say it's coming this quarter; so soon.
And then with regard to your question around 50%, I mean the market research is really interesting. The preference for an oral drug is so strong that you can vary the efficacy up to 85% all the way down to 55% and see small changes in preference share. So the point we're trying to make is there's just a really, really strong demand for an oral drug.